Aktienanalyse zu Omnicell Inc (OMCL)OMCLOmnicell Inc

Omnicell, Inc. is a healthcare technology provider focused on autonomous medication management, by unifying automation and AI-enabled intelligence, optimized by expert services, to drive clinical and business outcomes that are helping to improve efficiency and enhance patient safety for healthcare facilities. The Company is focused on helping its customers define and deliver a medication management strategy designed for pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. It provides a range of points of care medication and supplies dispensing systems, including automated systems and offers advanced automation solutions, including robotics designed to automate work, streamline workflows, and reduce human error. It provides central pharmacy automation solutions for both medication dispensing and IV compounding and provides patient engagement solutions. It operates in the Healthcare sector (ELECTRONIC COMPUTERS industry).

Omnicell Inc is not a good buy right now. The current price is $33.08, which is significantly lower than the analyst price targets ranging from $45 to $65, indicating potential upside. However, the RSI is at a very low 19.425, suggesting the stock is oversold, but the recent negative sentiment from insiders selling shares has increased by 151.38%. This raises concerns about the stock's short-term performance.

8 analysts cover OMCL: 5 rate it Buy, 3 Hold and 0 Sell. The average price target is 54.20.